Despite its small population, Slovenia is one of the most advanced pharmaceutical markets in Central and Eastern Europe, with the industry accounting for a major source of the country's GDP and poised for rapid growth. The main reasons for this are the relative wealth of the country, a long tradition of pharmaceutical manufacturing and a high level of connection with the EU and Western Europe in general. In 2017, the Slovenian drug market was valued at EUR755mn (USD853mn). Generic drugs, mostly of the sophisticated branded variety, and priced at up to 80% of the original product, represented a calculated 34% of the total market by value in 2017. The percentage share of patented drugs, which stood at 56% of total drug sales in 2017, is likely to fall modestly over the forecast period, largely due to the regulatory bias against patented drugs and patented expirations despite the continued high price of generic drugs. In the meantime, the need for cost containment in the public healthcare sphere will lead to higher volumes of generic medicines and has included a drive to reduce their prices. In 2017, pharmaceutical sales accounted for 1.7% of GDP and 21% of total health spending.

Key View

SWOT

Industry Forecast

Industry Risk/Reward Index

Regulatory Development

Market Overview

Competitive Landscape

Company Profile

Slovenia Demographic Outlook 

Pharmaceuticals & Healthcare Glossary 

Pharmaceuticals & Healthcare Methodology